Stocky turns companies like Eli Lilly and Company into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Strong Buy. LLY is a rare elite growth compounder (98/100 score) with 32%+ revenue growth driven by blockbuster GLP-1 therapies, paired with 28%+ ROIC and strong leadership alignment. Unanimous analyst bullishness and top-quartile alpha signal conviction, though GLP-1 concentration (~30%+ of revenue) and FDA cycle dependency create meaningful structural risk.
How safely Eli Lilly and Company is financed, graded A++ (strongest) to C from the last five years of accounts: debt against earnings, interest cover, cash against debt, how high and steady profit margins are, return on capital, and whether it generated cash every year. Not part of the Stocky score.
Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for Eli Lilly and Company:
Quality + moat + leadership + valuation fused into a single 0–100 number. When you see 94/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Eli Lilly and Company (LLY) at 94/100 — a strong Buy candidate. The score fuses business quality, moat width, leadership alignment, valuation into a single number. Strong Buy. LLY is a rare elite growth compounder (98/100 score) with 32%+ revenue growth driven by blockbuster GLP-1 therapies, paired with 28%+ ROIC and strong leadership alignment. Unanimous analyst bullishness and top-quartile alpha sig
LLY's current Stocky Verdict is 94/100, placing it in the "Strong Buy" band. This composite combines a 98/100 Compounder score, 75/100 Leadership, 100/100 Moat rating.
Eli Lilly and Company rates Wide moat (100/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.
Eli Lilly and Company scores 75/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Eli Lilly and Company's Resilience Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Eli Lilly and Company.
Sign up free and unlock the full analysis on LLY — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for LLY in the app.
